2-benzyloxy-5-phenylbenzaldehyde | 796047-10-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-benzyloxy-5-phenylbenzaldehyde
• 英文别名: 4-(Benzyloxy)[1,1'-biphenyl]-3-carbaldehyde；5-phenyl-2-phenylmethoxybenzaldehyde
• CAS: 796047-10-4
• 化学式: C₂₀H₁₆O₂
• mdl: MFCD06802226
• 分子量: 288.346
• InChiKey: FWLHXOWDYQRFJC-UHFFFAOYSA-N

物化性质

• 沸点：
  476.3±40.0 °C(Predicted)
• 密度：
  1.148±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-benzyloxy-5-phenylbenzaldehyde 在 哌啶 、 吡啶 、 四(三苯基膦)钯 、 草酰氯 、 palladium 10% on activated carbon 、 氨 、 氢气 、 potassium carbonate 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 、 乙酸乙酯 、 乙腈 为溶剂， 反应 28.25h， 生成 3-[4-(1H-indol-4-yl)biphenyl-3-yl]propanamide
  参考文献：
  名称：

  [EN] COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS
  [FR] COMPOSITIONS POUR LE TRAITEMENT DE L'HYPERTENSION ET/OU DE LA FIBROSE

  摘要：

  本发明涉及新化合物及其在预防性和/或治疗高血压和/或纤维化的用途。

  公开号：

  WO2015039172A1
• 作为产物：
  描述：

  苯硼酸 在 palladium diacetate 、 potassium carbonate 作用下， 以 水 、 乙腈 为溶剂， 反应 7.0h， 生成 2-benzyloxy-5-phenylbenzaldehyde
  参考文献：
  名称：

  [EN] COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS
  [FR] COMPOSITIONS POUR LE TRAITEMENT DE L'HYPERTENSION ET/OU DE LA FIBROSE

  摘要：

  本发明涉及新化合物及其在预防性和/或治疗高血压和/或纤维化的用途。

  公开号：

  WO2015039172A1

文献信息

• Thiazolidinedione derivatives as PTP1B inhibitors with antihyperglycemic and antiobesity effects
  作者：Bharat Raj Bhattarai、Bhooshan Kafle、Ji-Sun Hwang、Deegendra Khadka、Sun-Myung Lee、Jae-Seung Kang、Seung Wook Ham、Inn-Oc Han、Hwangseo Park、Hyeongjin Cho

  DOI：10.1016/j.bmcl.2009.09.020

  日期：2009.11

  Benzylidene-2,4-thiazolidinedione derivatives with substitutions on the phenyl ring at the ortho or para positions of the thiazolidinedione (TZD) group were synthesized as PTP1B inhibitors with IC50 values in a low micromolar range. Compound 3e, the lowest, bore an IC50 of 5.0 mu M. In vivo efficacy of 3e as an antiobesity and hypoglycemic agent was evaluated in a mouse model system. Significant improvement of glucose tolerance was observed. This compound also significantly suppressed weight gain and significantly improved blood parameters such as TG, total cholesterol and NEFA. Compound 3e was also found to activate peroxisome proliferator-activated receptors (PPARs) indicating multiple mechanisms of action. (c) 2009 Elsevier Ltd. All rights reserved.
• Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors
  作者：Jin Hee Ahn、Seung Jun Kim、Woul Seong Park、Sung Yun Cho、Jae Du Ha、Sung Soo Kim、Seung Kyu Kang、Dae Gwin Jeong、Suk-Kyeong Jung、Sang-Hyeup Lee、Hwan Mook Kim、Song Kyu Park、Ki Ho Lee、Chang Woo Lee、Seong Eon Ryu、Joong-Kwon Choi

  DOI：10.1016/j.bmcl.2006.02.060

  日期：2006.6

  A series of rhodanine derivatives was synthesized and evaluated for their ability to inhibit PRL-3. Benzylidene rhodanine derivative showed good biological activity, while compound 5e was the most active in this series exhibiting IC50 value of 0.9 mu M in vitro and showed a reduced invasion in cell-based assay. (c) 2006 Elsevier Ltd. All rights reserved.
• Synthesis and biological evaluation of thiazolidine-2,4-dione and 2,4-thione derivatives as inhibitors of translation initiation
  作者：Han Chen、Yun-Hua Fan、Amarnath Natarajan、Yuhong Guo、Julia Iyasere、Fred Harbinski、Lia Luus、William Christ、Huseyin Aktas、Jose A. Halperin

  DOI：10.1016/j.bmcl.2004.08.017

  日期：2004.11

  In an effort to generate novel translation initiation inhibitors for cancer therapy, a series of 2'-benzyloxy-5'-substituted-5-benzylidene-thiazolidine-2,4-thione and dione derivatives was synthesized and evaluated for activity in translation initiation specific assays. Several candidates of the 5-benzylidene-thiazolidine-2,4-diones (3c, 3d, and 3f) and -thiones (2b, 2e, and 2j), inhibit cell growth with low muM GI(50) mediated by inhibition of translation initiation, which involves partial depletion of intracellular Ca2+ stores and strong phosphorylation of eIF2alpha. (C) 2004 Elsevier Ltd. All rights reserved.
• COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS
  申请人：Vectus Biosystems Limited

  公开号：EP3046902B1

  公开（公告）日：2018-08-08
• US9630935B2
  申请人：——

  公开号：US9630935B2

  公开（公告）日：2017-04-25